HLB, an international biopharmaceutical company, submitted a new drug application (NDA) for its Rivoceranib liver cancer drug to the U.S. Food and Drug Administration (FDA) on Tuesday. If successful, it would become the first Korean biotechnology company to win a new drug approval in the U.S., the company said Thursday. 

Please refer to the following website for further details: https://www.koreatimes.co.kr/www/nation/2023/05/779_351238.html?utm_source=na